Intravenous Pamidronate in Juvenile Osteoporosis

Overview

Journal Arch Dis Child

Specialty Pediatrics

Date 2000 Jul 25

PMID 10906023

Citations 18

Authors

N J Shaw

C M Boivin

N J Crabtree

Affiliations

Soon will be listed here.

Abstract

Aims: To investigate the use of the aminobisphosphonate, disodium pamidronate, in children with vertebral osteoporosis.

Methods: Five children (aged 10-15 years) with vertebral osteoporosis who developed compression fractures in the thoracic and/or lumbar spine as a consequence of five different conditions, received treatment with intravenous disodium pamidronate in doses ranging from 0.5 to 12 mg/kg/y.

Results: Each child had rapid pain relief following the first treatment, followed by large increments in lumbar spine bone density over one year; the change in bone density standard deviation score ranged from 0.5 to 2.5 with percentage increments of 26% to 54%.

Conclusion: Intravenous pamidronate appears to be a useful therapeutic option in childhood osteoporosis, but its use in children must still be regarded as experimental and therefore closely monitored.

Citing Articles

Primary osteoporosis in children.

Tan L, Lim S, Vasanwala R BMJ Case Rep. 2017; 2017.

PMID: 28866630 PMC: 5589026. DOI: 10.1136/bcr-2017-220700.

Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy.

Bell J, Shields M, Watters J, Hamilton A, Beringer T, Elliott M Cochrane Database Syst Rev. 2017; 1:CD010899.

PMID: 28117876 PMC: 6464928. DOI: 10.1002/14651858.CD010899.pub2.

Efficacy of pamidronate in pediatric osteosarcoma patients with low bone mineral density.

Lim S, Ahn J, Choi A, Cho W, Lee J, Kim D Ann Pediatr Endocrinol Metab. 2016; 21(1):21-5.

PMID: 27104175 PMC: 4835557. DOI: 10.6065/apem.2016.21.1.21.

The Current and Future Therapies for Human Osteosarcoma.

Lamplot J, Denduluri S, Qin J, Li R, Liu X, Zhang H Curr Cancer Ther Rev. 2016; 9(1):55-77.

PMID: 26834515 PMC: 4730918. DOI: 10.2174/1573394711309010006.

Osteoporosis treatment with zoledronic acid in pediatric population at a university hospital in Western Saudi Arabia. A 13-year experience.

Al-Agha A, Hayatalhazmi R Saudi Med J. 2015; 36(11):1312-8.

PMID: 26593164 PMC: 4673368. DOI: 10.15537/smj.2015.11.12590.

References

Hoekman K, Papapoulos S, Peters A, BIJVOET O . Characteristics and bisphosphonate treatment of a patient with juvenile osteoporosis. J Clin Endocrinol Metab. 1985; 61(5):952-6. DOI: 10.1210/jcem-61-5-952. View

Rogers J, DORST J, Geho W . Use and complications of high-dose disodium etidronate therapy in fibrodysplasia ossificans progressiva. J Pediatr. 1977; 91(6):1011-4. DOI: 10.1016/s0022-3476(77)80918-9. View

Saggese G, Bertelloni S, Baroncelli G, Perri G, Calderazzi A . Mineral metabolism and calcitriol therapy in idiopathic juvenile osteoporosis. Am J Dis Child. 1991; 145(4):457-62. DOI: 10.1001/archpedi.1991.02160040119019. View

Nishioka T, Kurayama H, Yasuda T, Udagawa J, Matsumura C, Niimi H . Nasal administration of salmon calcitonin for prevention of glucocorticoid-induced osteoporosis in children with nephrosis. J Pediatr. 1991; 118(5):703-7. DOI: 10.1016/s0022-3476(05)80030-7. View

Lepore L, Pennesi M, Barbi E, Pozzi R . Treatment and prevention of osteoporosis in juvenile chronic arthritis with disodium clodronate. Clin Exp Rheumatol. 1991; 9 Suppl 6:33-5. View

van Persijn van Meerten E, Kroon H, Papapoulos S . Epi- and metaphyseal changes in children caused by administration of bisphosphonates. Radiology. 1992; 184(1):249-54. DOI: 10.1148/radiology.184.1.1609087. View

Adamson B, Gallacher S, Byars J, Ralston S, Boyle I, Boyce B . Mineralisation defects with pamidronate therapy for Paget's disease. Lancet. 1993; 342(8885):1459-60. DOI: 10.1016/0140-6736(93)92935-m. View

Liens D, Delmas P, Meunier P . Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. Lancet. 1994; 343(8903):953-4. DOI: 10.1016/s0140-6736(94)90069-8. View

Brenner R, Vetter U, Bollen A, Morike M, Eyre D . Bone resorption assessed by immunoassay of urinary cross-linked collagen peptides in patients with osteogenesis imperfecta. J Bone Miner Res. 1994; 9(7):993-7. DOI: 10.1002/jbmr.5650090706. View

10.

Shaw N, White C, Fraser W, Rosenbloom L . Osteopenia in cerebral palsy. Arch Dis Child. 1994; 71(3):235-8. PMC: 1029978. DOI: 10.1136/adc.71.3.235. View

11.

Prentice A, Parsons T, Cole T . Uncritical use of bone mineral density in absorptiometry may lead to size-related artifacts in the identification of bone mineral determinants. Am J Clin Nutr. 1994; 60(6):837-42. DOI: 10.1093/ajcn/60.6.837. View

12.

Smith R . Idiopathic juvenile osteoporosis: experience of twenty-one patients. Br J Rheumatol. 1995; 34(1):68-77. DOI: 10.1093/rheumatology/34.1.68. View

13.

Leong G, Mercado-Asis L, Reynolds J, Hill S, Oldfield E, Chrousos G . The effect of Cushing's disease on bone mineral density, body composition, growth, and puberty: a report of an identical adolescent twin pair. J Clin Endocrinol Metab. 1996; 81(5):1905-11. DOI: 10.1210/jcem.81.5.8626856. View

14.

Boot A, de Ridder M, Pols H, Krenning E, de Muinck Keizer-Schrama S . Bone mineral density in children and adolescents: relation to puberty, calcium intake, and physical activity. J Clin Endocrinol Metab. 1997; 82(1):57-62. DOI: 10.1210/jcem.82.1.3665. View

15.

Allgrove J . Biphosphonates. Arch Dis Child. 1997; 76(1):73-5. PMC: 1717046. DOI: 10.1136/adc.76.1.73. View

16.

Adachi J, Bensen W, Brown J, Hanley D, Hodsman A, Josse R . Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med. 1997; 337(6):382-7. DOI: 10.1056/NEJM199708073370603. View

17.

Brumsen C, Hamdy N, Papapoulos S . Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Medicine (Baltimore). 1997; 76(4):266-83. DOI: 10.1097/00005792-199707000-00005. View

18.

Glorieux F, Bishop N, Plotkin H, Chabot G, Lanoue G, Travers R . Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998; 339(14):947-52. DOI: 10.1056/NEJM199810013391402. View

19.

Eastell R, Reid D, Compston J, Cooper C, Fogelman I, Francis R . A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med. 1998; 244(4):271-92. DOI: 10.1046/j.1365-2796.1998.00408.x. View

20.

Shoemaker L . Expanding role of bisphosphonate therapy in children. J Pediatr. 1999; 134(3):264-7. DOI: 10.1016/s0022-3476(99)70447-6. View